CIDM vs. BTX, ALFIW, and NLOK
Should you be buying Cinedigm stock or one of its competitors? The main competitors of Cinedigm include Brooklyn ImmunoTherapeutics (BTX), Alfi (ALFIW), and NortonLifeLock (NLOK). These companies are all part of the "information" sector.
Cinedigm (NASDAQ:CIDM) and Brooklyn ImmunoTherapeutics (NYSE:BTX) are both small-cap information companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
In the previous week, Cinedigm had 1 more articles in the media than Brooklyn ImmunoTherapeutics. MarketBeat recorded 1 mentions for Cinedigm and 0 mentions for Brooklyn ImmunoTherapeutics. Cinedigm's average media sentiment score of 0.00 equaled Brooklyn ImmunoTherapeutics'average media sentiment score.
Cinedigm has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Comparatively, Brooklyn ImmunoTherapeutics has a beta of 4.61, suggesting that its share price is 361% more volatile than the S&P 500.
Brooklyn ImmunoTherapeutics has lower revenue, but higher earnings than Cinedigm. Cinedigm is trading at a lower price-to-earnings ratio than Brooklyn ImmunoTherapeutics, indicating that it is currently the more affordable of the two stocks.
8.0% of Cinedigm shares are held by institutional investors. Comparatively, 26.0% of Brooklyn ImmunoTherapeutics shares are held by institutional investors. 16.4% of Cinedigm shares are held by insiders. Comparatively, 20.5% of Brooklyn ImmunoTherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Cinedigm and Brooklyn ImmunoTherapeutics both received 0 outperform votes by MarketBeat users.
Summary
Brooklyn ImmunoTherapeutics beats Cinedigm on 4 of the 7 factors compared between the two stocks.
Get Cinedigm News Delivered to You Automatically
Sign up to receive the latest news and ratings for CIDM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CIDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cinedigm Competitors List
Related Companies and Tools
